Episode
Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor
- Podcast
- Business Of Biotech
- Published
- Apr 6, 2026
- Duration seconds
- 2426
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/radiotherapeutics-for-neuroendocrine-tumors-with-perspective-therapeutics-thijs-spoor.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Thijs Spoor, CEO at Perspective Therapeutics, a company developing Pb 212 (lead)-based therapeutics, talks about why radiopharmaceuticals are surging again and why biodistribution is the make-or-break variable when your payload is a radioactive isotope. Thijs discusses the reasons behind Perspective's investment in a proprietary generator for therapeutic production, manufacturing a...